Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies.

Research output: Contribution to journalReview article

Abstract

Along with greater life expectancy in patients with haemophilia has been an increase in associated haemophilia-related (arthropathy, osteoporosis, viral infections) and age-related (cardiovascular disease, renal disease, cancer and others) comorbidities, many of which are only just emerging as the population ages. At present, experience in managing these comorbidities is limited. As the demographic shift continues, haemophilia care centres can expect to encounter more patients with greater levels of complexity. In the absence of evidence-based information to guide the management of adult patients with haemophilia, it is important that the scientific position be reviewed on a regular basis. To this end, several topics relevant to the clinical management of adult patients with haemophilia were examined in a symposium entitled Comorbidities and inhibitors in adult patients with haemophilia: issues, costs and management strategies held on 11 February 2015 in Helsinki, Finland, in conjunction with the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders. This article is a summary of that event.

Details

Authors
  • Erik Berntorp
  • Evelien Mauser-Bunschoten
  • Víctor Jiménez-Yuste
  • Jeffrey B Spears
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Hematology
Original languageEnglish
Pages (from-to)1-15
JournalEuropean Journal of Haematology
Volume95
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes